Allogene Therapeutics Prepares for First Quarter 2025 Financial Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a pioneering clinical-stage biotechnology company focused on the development of allogeneic CAR T (AlloCAR T™) products aimed at combatting cancer and autoimmune diseases, is gearing up to share its financial results for the first quarter of 2025. The announcement is set to take place on May 13, 2025, right after market closure.
Upcoming Conference Call and Webcast
Following the financial announcement, Allogene will host a live audio webcast and conference call scheduled for 2:00 p.m. PT/5:00 p.m. ET. This is an excellent opportunity for shareholders and interested parties to gain valuable insights into the company's financial standing and strategic direction.
How to Access the Webcast
Investors and the interested public can tune into the webcast available on Allogene's official website under the Investors tab in the News and Events section. This listen-only event ensures that participants can follow along as updates unfold. Post-event, a replay will be made available online for approximately 30 days, allowing those unable to attend live to catch up on what they missed.
Registering for the Conference Call
For those wanting the chance to ask questions during the conference call, registration is essential. Individuals can follow a simple registration link provided on the company website to secure a personal PIN, allowing them to participate actively in the call.
Introduction to Allogene Therapeutics
Based in South San Francisco, Allogene Therapeutics stands at the forefront of biotechnological innovation, especially in the realm of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products. The leadership team possesses substantial experience in cell therapy, positioning Allogene to pioneer breakthrough therapies designed to be available when needed. The company is focused on creating “off-the-shelf” CAR T cell product candidates aimed at streamlining therapeutic access for patients.
Commitment to Advancing Cancer Treatments
Allogene's goal is to enhance the availability of life-saving treatments through more reliable, scalable solutions for patients in need. Their approach places emphasis on making cell therapy more accessible, which could have a significant impact on the treatment landscape for cancer and autoimmune diseases.
Engaging with Allogene Therapeutics
For the latest updates and in-depth information, stakeholders are encouraged to visit Allogene's official website. The company remains active on social media platforms such as X and LinkedIn, providing additional venues for engagement and information sharing.
Contact Information for Media and Investors
For any media inquiries or further information, Christine Cassiano, EVP and Chief Corporate Affairs & Brand Strategy Officer, is the direct contact. She can be reached via email for those seeking additional insights into Allogene’s operations and forthcoming opportunities.
Frequently Asked Questions
What is the date for Allogene Therapeutics’ financial report?
The financial report for Q1 2025 will be announced on May 13, 2025.
How can I access the webcast for the financial results?
The webcast will be available on Allogene’s official website under the Investors tab in the News and Events section.
Is there a chance to ask questions during the conference call?
Yes, interested parties can register to ask questions by following the provided registration link on Allogene's website.
What areas does Allogene Therapeutics focus on?
Allogene specializes in developing allogeneic CAR T products aimed at treating cancer and autoimmune diseases.
Who can I contact for more information about Allogene?
You can reach Christine Cassiano, EVP, at her email address for any media or investor inquiries.
